Tumor microenvironment

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Retrieved on: 
четверг, мая 30, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Relapse, Follicular lymphoma, Paclitaxel, Finish line, Drug development, Metastatic breast cancer, Breast cancer, Tumor microenvironment, Sarah Cannon Research Institute, Breast, Lead, Master, Consolidation, HealthOne, Durvalumab, Meta-analysis, CDT, OU Health, Total cost, PD-L1, Survival, Clinical trial, Quality, MPH, Endometrial cancer, NSCLC, SCRI, ASCO, Safety, BCMA, Society, Cetuximab, Doctor of Philosophy, Efficacy, Spacecraft, Metastasis, Monoclonal antibody, Acute myeloid leukemia, Abstract, HCA Healthcare, Role, Annual general meeting, Birth control

“We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.

Key Points: 
  • “We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.
  • To learn more about our research experts, visit our Leadership Page .
  • “Clinical Trial Participation and End-of-Life Care Among Older Adults: A Multi-Center Longitudinal Observational Cohort Analysis of 121,717 Patients with Cancer,” Dr.
  • “Performance of Comprehensive Genomic Profiling versus Single Gene Testing in Guideline-Recommended Biomarker Selection in Non-Small Cell Lung Cancer,” Dr. V. Subbiah, 1:30 p.m. - 4:30 p.m. CDT, Hall A.

Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors

Retrieved on: 
четверг, мая 30, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Pharmacokinetics, Pembrolizumab, PD, NK, Messenger, Tumor microenvironment, Therapy, Neoplasm, Safety, Cancer, ASCO, Society, Immunotherapy, Entrepreneurship, Annual general meeting

Strand Therapeutics , the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.

Key Points: 
  • Strand Therapeutics , the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.
  • “STX-001 represents the first programmable mRNA therapy in oncology to enter the clinic for the treatment of solid tumors,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics.
  • Strand will present a poster on the Phase 1 trial design.
  • The Phase 1 trial is an open-label, multi-center first-in-human dose-escalation trial, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of STX-001 alone, or in combination with pembrolizumab in patients with treatment refractory advanced solid tumors.

Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch

Retrieved on: 
среда, мая 29, 2024
Patient, CD4, Investigational New Drug, Health, News, Science, Food, Translation, Clinical trial, Tumor microenvironment, FDA, IND, Cancer, Immunotherapy, CD8, Vaccine

The news comes just on the heels of the company’s first-in-class, dual-functioning antibody, GIM-122, progressing to clinical trial for human testing.

Key Points: 
  • The news comes just on the heels of the company’s first-in-class, dual-functioning antibody, GIM-122, progressing to clinical trial for human testing.
  • T regulatory cells are immune cells that play a critical role in inhibiting the immune response against cancer.
  • “At a time when current cancer treatment options often fail to help patients who don’t respond to checkpoint inhibitors, Georgiamune is dedicated to creating novel drugs that address this critical unmet need.
  • “Georgiamune’s therapeutic approach to cancer treatment aligns with our Health Assurance thesis, and we look forward to the company’s progress at its clinical trial stage.”

BostonGene Announces Seven Abstract Acceptances at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
среда, мая 29, 2024
Oncology, Health, Technology, Other Health, Artificial Intelligence, Pharmaceutical, Biotechnology, NGS, Patient, MD Anderson Cancer Center, ILC, Mayo Clinic, University, NEC, TME, H&E, Colorectal cancer, Clinical trial, Tumor microenvironment, Duke Cancer Institute, FDA, Therapy, Sarcoma, Breast cancer, Neoplasm, Research, Glomus tumor, WES, Biomarker, CRC, Journal, RNA, Abstract, Classification, Breast, CCNG1, B cell, Expression, RNA-Seq, City, Medical imaging

These findings highlight the importance of RNA-seq to advance research and identify potential biomarkers for sarcomas.

Key Points: 
  • These findings highlight the importance of RNA-seq to advance research and identify potential biomarkers for sarcomas.
  • In this study, single-cell RNA-seq was used to investigate the connection between breast cancer classification and luminal expression profiles.
  • Research conducted in collaboration with City of Hope Comprehensive Cancer Center, Sarcoma Oncology Center, Duke University and Expression Therapeutics
    For more information, please visit the 2024 ASCO Annual Meeting website .
  • The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

Retrieved on: 
четверг, мая 23, 2024
MSD, Pembrolizumab, Merck & Co., Patient, Oxidative stress, TPS, Trastuzumab, Science, HER2, Proteostasis, Tumor microenvironment, FDA, Endometrial cancer, Safety, Breast cancer, ADC, Senior, Headquarters, LEAP, Research, Deep, Cancer, Drug discovery, ASCO, Merck, PRISM, Society, Apoptosis, Hepatocellular carcinoma, Differentiable function, Inflammation, Hypoxia, Annual general meeting, Pharmaceutical industry

TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.

Key Points: 
  • TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.
  • (1) KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Retrieved on: 
пятница, мая 24, 2024
Radiation therapy, Peking Union Medical College, EP4, Esophageal cancer, Medicine, ANL, Clinical trial, Tumor microenvironment, Trial of the century, Safety, Neoadjuvant therapy, Macrophage, ASCO, Hospital, Society, CRT, Annual general meeting, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.
  • AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrophages and immunosuppressive myeloid cells in tumor microenvironment.
  • The combination of AN0025 with CRT as neoadjuvant therapy has shown synergistic antitumor efficacy in locally advanced rectal cancer in a prior clinical trial (NCT03152370).
  • The AN0025S0104 study is a single-arm, open-label, multicenter, Phase Ib study comprising a dose escalation phase followed by an expansion phase, aimed at evaluating the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or locally recurrent EC or esophagogastric junction cancer.

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
четверг, мая 23, 2024
CHRS, Immunosuppression, Half-life, McCormick Place, Patient, CCR8, Immunoglobulin G, TME, Tumor microenvironment, Neoplasm, Poster, Safety, Death, PD-1, GPCR, ASCO, Infrared spectroscopy correlation table, Aes, IO, SAE, Vaccine

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago. CHS-114 is a novel afucosylated human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding. CCR8 is a G protein-coupled receptor (GPCR) that shows preferential expression on tumor resident Treg cells and has promise as a drug target for selectively targeting immune suppression in the tumor microenvironment (TME) without broadly depleting Treg cells, which has the known unwanted side effect of autoimmune activation.

Key Points: 
  • “The Phase 1 preliminary dose escalation results are an important milestone as we progress our innovative I-O pipeline.
  • Abstract # 2664: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors.
  • Preliminary results and acceptable safety profile support further evaluation of CHS-114 in combination treatment with toripalimab and other I-O agents.
  • In 19 patients evaluable for response, no objective responses were yet noted, while the stable disease rate was 47%.

Purple Biotech Reports First Quarter 2024 Financial Results

Retrieved on: 
вторник, мая 21, 2024
Net, Risk, Tumor microenvironment, SCCHN, FDA, Pancreatic cancer, CA19-9, Oncology, Randomness, NK, Escape Room, Recurrence, AACR, Cancer, STAT3, Table, B cell, Administration, Phase II, PDAC, Average cost, Neoplasm, Safety, Jefferies Group, NSCLC, ADS, Interim, ASCO, Poster, International, Society, Drug resistance, SAB, IGF1R, Nivolumab, Cetuximab, DCR, Patient, Quarter, Pharmacodynamics, Death, Efficacy, CM24, Biomarker, SOC, Annual general meeting, Pharmaceutical industry

REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024.

Key Points: 
  • REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024.
  • Financial Results for the Quarter Ended March 31, 2024
    Research and Development Expenses were $3.4 million for the three months ended March 31, 2024, a decrease of $0.1 million, or 2.8%, compared to $3.5 million in the same period of 2023.
  • As of March 31, 2024, Purple Biotech had cash and cash equivalents and short-term deposits of $10.8 million.
  • A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

Retrieved on: 
понедельник, мая 20, 2024
Uveal melanoma, MPH, Pancreatic serous cystadenoma, Patent, Tumor microenvironment, MD, Tokyo Stock Exchange, Metastasis, CD8, Code, Vaccine

Once issued, this patent is expected to expire no earlier than July 2042.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than July 2042.
  • The allowed claims cover the use of MN-166 (ibudilast) for preventing, ameliorating, or minimizing metastasis of eye cancer.
  • The allowed claims specifically cover the use of MN-166 (ibudilast) for preventing, ameliorating, or minimizing metastasis of uveal melanoma.
  • We are gratified that this new patent will enhance potential value of MN-166 (ibudilast) in the oncology field.”

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Retrieved on: 
вторник, мая 14, 2024
Patient, Stomatitis, DL2, Plasma, PD, T-cell prolymphocytic leukemia, Relapse, ALT, Nausea, Tumor microenvironment, CTCL, Therapy, Neoplasm, Arthralgia, Safety, Constipation, Lymphoma, MD, T-PLL, EHA, PTCL, STAT3, Cutaneous T-cell lymphoma, Biomarker, CHL, Fatigue, Infrared spectroscopy correlation table, Peripheral T-cell lymphoma, TPD, European Hematology Association, SOCS3, Annual general meeting

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) --  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new Phase 1 data for KT-333, a first-in-class degrader of STAT3, highlighting safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical responses will be presented at the European Hematology Association (EHA) Annual Meeting, taking place from June 13-16, 2024, in Madrid, Spain. Results released in an EHA abstract today, which include a data cut-off as of February 6, 2024, demonstrate that KT-333 is a potent and selective STAT3 degrader that has demonstrated clinically significant responses in specific patient populations. The poster presentation is expected to include additional data, including PK/PD, safety and results of disease response assessments from additional patients subsequent to the abstract cut-off date.

Key Points: 
  • The poster presentation is expected to include additional data, including PK/PD, safety and results of disease response assessments from additional patients subsequent to the abstract cut-off date.
  • “We’re encouraged by the Phase 1 data generated to date.
  • We have also achieved substantial target knockdown and pathway activation,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics.
  • Title: Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers